Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Survey Study of Gastroenterologists’ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease
Laurie B. Grossberg, Konstantinos Papamichael, Joseph D. Feuerstein, et al.
Inflammatory Bowel Diseases (2017) Vol. 24, Iss. 1, pp. 191-197
Open Access | Times Cited: 42

Showing 26-50 of 42 citing articles:

Infliximab monitoring in Crohn’s disease: a neural network approach for evaluating disease activity and immunogenicity
Luís Eduardo Miani Gomes, Lívia Moreira Genaro, Marina Moreira de Castro, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis
Dena Zeraatkar, Tyler Pitre, Sarah Kirsh, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000998-e000998
Open Access | Times Cited: 1
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
K. H. Bjørlykke, Jørgen Jahnsen, Jørn Brynskov, et al.
Scandinavian Journal of Gastroenterology (2022) Vol. 58, Iss. 1, pp. 25-33
Open Access | Times Cited: 6
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
Silje Watterdal Syversen, Johanna Elin Gehin, Guro Løvik Goll, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 5, pp. 667-669
Open Access | Times Cited: 3
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
Benjamin Click, Edward L. Barnes, Benjamin L. Cohen, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia
Chenwen Cai, Juntao Lu, Lijie Lai, et al.
Intestinal Research (2022) Vol. 20, Iss. 2, pp. 213-223
Open Access | Times Cited: 5
Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
Stéphane Paul, Hubert Marotte, Arthur Kavanaugh, et al.
Clinical and Translational Science (2020) Vol. 13, Iss. 4, pp. 743-751
Open Access | Times Cited: 6
Real-world impact of infliximab precision-guided dosing on management of patients with IBD
Bincy Abraham, David Ziring, Thierry Dervieux, et al.
The American Journal of Managed Care (2023) Vol. 29, Iss. Suppl 12, pp. S227-S235
Open Access | Times Cited: 2
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East
Gaurav Nigam, Kelly Chatten, Ala I. Sharara, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis
Yang Hu, Zaiwei Song, Yuan Gao, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 10, pp. 935-948
Open Access
Monitoramento terapêutico de Infliximabe na doença de Crohn
Luís Eduardo Miani Gomes
(2024)
Closed Access
Fecal lactoferrin predicts primary non-response to biologic agents in inflammatory bowel disease
Dario Sorrentino, Vu Q. Nguyen, Kim Love
Digestive Diseases (2021) Vol. 39, Iss. 6, pp. 626-633
Open Access | Times Cited: 4
Knowledge, Confidence, and Perception Toward Therapeutic Drug Monitoring Among Physicians and Pharmacists in Kuwait
Abdullah Albassam, Sarah S. Alghanem, Fahimah Al-Awadhi, et al.
Therapeutic Drug Monitoring (2022) Vol. 44, Iss. 4, pp. 511-519
Open Access | Times Cited: 2
Therapeutic drug monitoring for biological medications in inflammatory bowel disease
Rachel C. Cogan, Basem W. El-Matary, Wael El‐Matary
Saudi Journal of Gastroenterology (2022) Vol. 28, Iss. 5, pp. 322-331
Open Access | Times Cited: 2
Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
Konstantinos Papamichael, Valerio J. Thomas, Andrea Banty, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2840-2840
Open Access | Times Cited: 2
Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
Israa Abdullah, Ghadeer Alhendi, Anwar Alhadab, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 1
Utilidad de la monitorización terapéutica de infliximab en el manejo de la enfermedad inflamatoria intestinal
Rodrigo Quera, Moreno Mauricio, Daniela Simian, et al.
Revista médica de Chile (2018) Vol. 146, Iss. 11, pp. 1241-1251
Open Access
Previous Page - Page 2

Scroll to top